Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 92

1.

Dopamine neuron dependent behaviors mediated by glutamate cotransmission.

Mingote S, Chuhma N, Kalmbach A, Thomsen GM, Wang Y, Mihali A, Sferrazza C, Zucker-Scharff I, Siena AC, Welch MG, Lizardi-Ortiz J, Sulzer D, Moore H, Gaisler-Salomon I, Rayport S.

Elife. 2017 Jul 13;6. pii: e27566. doi: 10.7554/eLife.27566.

2.

No association between SLC6A2, SLC6A3, DRD2 polymorphisms and schizophrenia in the Han Chinese population.

Bi Y, Huang X, Niu W, Chen S, Wu X, Cao Y, Zhang R, Yang F, Wang L, Li W, Xu Y, He L, Yu T, He G, Li X.

Psychiatry Res. 2017 Jul;253:398-400. doi: 10.1016/j.psychres.2017.02.051. Epub 2017 Feb 27.

PMID:
28454051
3.

GeneAnalytics Pathway Analysis and Genetic Overlap among Autism Spectrum Disorder, Bipolar Disorder and Schizophrenia.

Khanzada NS, Butler MG, Manzardo AM.

Int J Mol Sci. 2017 Feb 28;18(3). pii: E527. doi: 10.3390/ijms18030527.

4.

Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia.

Eisenstein SA, Bogdan R, Chen L, Moerlein SM, Black KJ, Perlmutter JS, Hershey T, Barch DM.

J Psychiatr Res. 2017 Mar;86:9-17. doi: 10.1016/j.jpsychires.2016.11.007. Epub 2016 Nov 17.

5.

Human Laboratory Studies on Cannabinoids and Psychosis.

Sherif M, Radhakrishnan R, D'Souza DC, Ranganathan M.

Biol Psychiatry. 2016 Apr 1;79(7):526-38. doi: 10.1016/j.biopsych.2016.01.011. Epub 2016 Feb 2. Review.

PMID:
26970363
6.

Increased Nigral SLC6A3 Activity in Schizophrenia Patients: Findings From the Toronto-McLean Cohorts.

Kennedy JL, Xiong N, Yu J, Zai CC, Pouget JG, Li J, Liu K, Qing H, Wang T, Martin E, Levy DL, Lin Z.

Schizophr Bull. 2016 May;42(3):772-81. doi: 10.1093/schbul/sbv191. Epub 2015 Dec 26.

7.

Genetic assessment of additional endophenotypes from the Consortium on the Genetics of Schizophrenia Family Study.

Greenwood TA, Lazzeroni LC, Calkins ME, Freedman R, Green MF, Gur RE, Gur RC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL.

Schizophr Res. 2016 Jan;170(1):30-40. doi: 10.1016/j.schres.2015.11.008. Epub 2015 Nov 18. Review.

8.

Identification of rare high-risk copy number variants affecting the dopamine transporter gene in mental disorders.

Hoeffding LK, Duong LT, Ingason A, Rosengren A, Sorbanski E, Witt SH, Djurovic S, Andreassen OA, Hansen T, Werge T, Rasmussen HB.

Nord J Psychiatry. 2016;70(4):276-9. doi: 10.3109/08039488.2015.1095944. Epub 2015 Nov 11.

PMID:
26559242
9.

Synergistic association of PI4KA and GRM3 genetic polymorphisms with poor antipsychotic response in south Indian schizophrenia patients with low severity of illness.

Kaur H, Jajodia A, Grover S, Baghel R, Jain S, Kukreti R.

Am J Med Genet B Neuropsychiatr Genet. 2014 Dec;165B(8):635-46. doi: 10.1002/ajmg.b.32268. Epub 2014 Sep 11.

PMID:
25209194
10.

Genetic variations of PIP4K2A confer vulnerability to poor antipsychotic response in severely ill schizophrenia patients.

Kaur H, Jajodia A, Grover S, Baghel R, Gupta M, Jain S, Kukreti R.

PLoS One. 2014 Jul 15;9(7):e102556. doi: 10.1371/journal.pone.0102556. eCollection 2014.

11.

No association of SLC6A3 and SLC6A4 gene polymorphisms with schizophrenia in the Han Chinese population.

Yang B, Huang X, Ruan L, Yu T, Li X, Jesse FF, Cao Y, Li X, Liu B, Yang F, Lee YS, He L, Li W, He G.

Neurosci Lett. 2014 Sep 5;579:114-8. doi: 10.1016/j.neulet.2014.07.004. Epub 2014 Jul 11.

PMID:
25019689
12.

Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.

Tybura P, Trześniowska-Drukała B, Bienkowski P, Beszlej A, Frydecka D, Mierzejewski P, Samochowiec A, Grzywacz A, Samochowiec J.

Psychiatry Res. 2014 Oct 30;219(2):261-7. doi: 10.1016/j.psychres.2014.05.039. Epub 2014 Jun 2.

PMID:
24930580
13.

Further evidence for the association between a polymorphism in the promoter region of SLC6A3/DAT1 and ADHD: findings from a sample of adults.

de Azeredo LA, Rovaris DL, Mota NR, Polina ER, Marques FZ, Contini V, Vitola ES, Belmonte-de-Abreu P, Rohde LA, Grevet EH, Bau CH.

Eur Arch Psychiatry Clin Neurosci. 2014 Aug;264(5):401-8. doi: 10.1007/s00406-014-0486-8. Epub 2014 Feb 1. Erratum in: Eur Arch Psychiatry Clin Neurosci. 2016 Oct 17;:.

PMID:
24487615
14.

The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.

Zivković M, Mihaljević-Peles A, Bozina N, Sagud M, Nikolac-Perkovic M, Vuksan-Cusa B, Muck-Seler D.

J Clin Psychopharmacol. 2013 Oct;33(5):593-9. doi: 10.1097/JCP.0b013e31829abec9.

PMID:
23963056
15.

Dopaminergic gene polymorphisms and cognitive function in a north Indian schizophrenia cohort.

Kukshal P, Kodavali VC, Srivastava V, Wood J, McClain L, Bhatia T, Bhagwat AM, Deshpande SN, Nimgaonkar VL, Thelma BK.

J Psychiatr Res. 2013 Nov;47(11):1615-22. doi: 10.1016/j.jpsychires.2013.07.007. Epub 2013 Aug 8.

16.

Dopaminergic foundations of schizotypy as measured by the German version of the Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE)-a suitable endophenotype of schizophrenia.

Grant P, Kuepper Y, Mueller EA, Wielpuetz C, Mason O, Hennig J.

Front Hum Neurosci. 2013 Jan 24;7:1. doi: 10.3389/fnhum.2013.00001. eCollection 2013.

17.

Lack of association between the G-660C polymorphism in the dopamine transporter gene (SLC6A3) and schizophrenia in the Iranian population.

Foroughmand AM, Galehdari H, Dastgerdi BT, Khatami SR, Haidari M.

Indian J Hum Genet. 2012 May;18(2):222-5. doi: 10.4103/0971-6866.100773.

18.

DNA methylation and expression profiles of the brain-derived neurotrophic factor (BDNF) and dopamine transporter (DAT1) genes in patients with schizophrenia.

Kordi-Tamandani DM, Sahranavard R, Torkamanzehi A.

Mol Biol Rep. 2012 Dec;39(12):10889-93. doi: 10.1007/s11033-012-1986-0. Epub 2012 Oct 14.

PMID:
23065263
19.

Visualization of the cocaine-sensitive dopamine transporter with ligand-conjugated quantum dots.

Kovtun O, Tomlinson ID, Sakrikar DS, Chang JC, Blakely RD, Rosenthal SJ.

ACS Chem Neurosci. 2011 Jul 20;2(7):370-8. doi: 10.1021/cn200032r. Epub 2011 Apr 26.

20.

Serotonergic involvement in the amelioration of behavioral abnormalities in dopamine transporter knockout mice by nicotine.

Uchiumi O, Kasahara Y, Fukui A, Hall FS, Uhl GR, Sora I.

Neuropharmacology. 2013 Jan;64:348-56. doi: 10.1016/j.neuropharm.2012.07.016. Epub 2012 Jul 15.

Supplemental Content

Loading ...
Support Center